

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

2024 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “RemeGen Co., Ltd. 2024 Third Quarterly Report” published by RemeGen Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2024 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board of directors of the Company (the “**Board**”) reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2024 Third Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board

RemeGen Co., Ltd.*

Mr. Wang Weidong

Chairman and executive director

Yantai, PRC
October 29, 2024

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* For identification purpose only

Stock Code: 688331

Ticker Symbol: RemeGen

RemeGen Co., Ltd.*

2024 THIRD QUARTERLY REPORT

The board of directors and all directors of the Company undertake that there are no false representations or misleading statements contained in, or material omissions from, this announcement, and accept responsibilities for the truthfulness, accuracy and completeness of its contents in accordance with the applicable laws.

IMPORTANT NOTICE:

The board of directors, supervisory committee, directors, supervisors and senior management of the Company undertake that the content of the quarterly report is true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The Company's legal representative, person in charge of accounting function and person in charge of the accounting department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report.

Whether the third quarterly financial statements have been audited:

Yes No

I. KEY FINANCIAL INFORMATION

(i) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Item	The Reporting Period	Increase/decrease compared with the same period of the previous year (%)	From the beginning of the year to the end of the Reporting Period	Increase/decrease compared with the same period of the previous year (%)
Operating revenue	467,117,500.34	34.60	1,208,874,280.23	57.10
Net profit attributable to shareholders of the listed company	-290,966,871.21	N/A	-1,071,426,638.90	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	-303,520,172.06	N/A	-1,097,393,812.12	N/A
Net cash flows from operating activities	N/A	N/A	-835,103,066.88	N/A
Basic earnings per share (RMB/share)	-0.54	N/A	-1.99	N/A
Diluted earnings per share (RMB/share)	-0.54	N/A	-1.99	N/A
Weighted average return on equity (%)	-11.30	A decrease of 9.53 percentage points	-36.92	A decrease of 20.05 percentage points
Total R&D spending	347,174,784.03	9.34	1,153,407,440.34	34.43
R&D spending as a percentage of operating revenue (%)	74.32	A decrease of 17.17 percentage points	95.41	A decrease of 16.09 percentage points
	As at the end of the Reporting Period		As at the end of the previous year	Increase/decrease compared with the end of the previous year (%)
Total assets	5,712,713,413.00		5,528,240,704.59	3.34
Owners' equity attributable to shareholders of the listed company	2,368,680,538.81		3,437,268,153.89	-31.09

Note: "The Reporting Period" means the three-month period from the beginning of the quarter to the end of the quarter, the same hereinafter.

(ii) Non-recurring items and amounts

✓ Applicable Not Applicable

Unit: RMB Currency: Renminbi

Non-recurring items	Current amount	Amount from the beginning of the year to the end of the Reporting Period	Description
Gains or losses on disposal of non-current assets, including the write-off of the asset impairment provisions	862.91	-96,891.94	Net gains or losses on disposal of non-current assets
Government grants recognised as current gains and losses, except those that are closely related to the Company's ordinary course of business operations, comply with national policies, granted based on determined standards, and have a lasting impact on the Company's profits and losses	17,816,478.70	39,903,684.46	Government grants recognised as other income
Gains and losses from changes in fair value arising from financial assets and financial liabilities held by non-financial enterprises and profits and losses from disposal of financial assets and financial liabilities other than effective hedging business related to the Company's ordinary course of business operations	1,301,638.89	1,539,972.22	Gains from structured deposits
Other non-operating income and expenses other than the above items	-6,565,679.65	-15,379,591.52	Donation expenses in majority
Other gains and losses items classified to non-recurring gains and losses	-	-	
Less: Impact on income tax	-	-	
Impact on non-controlling interests (after tax)	-	-	
Total	12,553,300.85	25,967,173.22	

Explanations are required for defining items that are not set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recurring Gains and Losses as non-recurring items with significant amounts and for defining the non-recurring items that are set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recurring Gains and Losses as recurring items.

√ Applicable Not Applicable

Unit: RMB Currency: Renminbi

Item	Amount involved	Reason
Additional value-added tax deductions	18,250,058.73	Tax incentives for business activities
Government grants related to long-term assets	7,086,786.96	Lasting impact on the Company's gains and losses

(iii) Changes in key accounting data and financial indicators and reasons for changes√ Applicable Not Applicable

Item	Percentage change (%)	Primary reason
Operating revenue_The Reporting Period	34.60	This was largely due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection.
Operating revenue_From the beginning of the year to the end of the Reporting Period	57.10	This was largely due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection.
Total R&D spending_From the beginning of the year to the end of the Reporting Period	34.43	This was largely due to the increase in R&D pipelines for new drugs and the increase in R&D spending as a result of a number of innovative drugs being at the critical experimental study stage and especially the accelerated progress in overseas clinical trials during the period.
Owners' equity attributable to shareholders of the listed company_At the end of the Reporting Period	-31.09	This was largely due to the increase in losses and the decrease in retained earnings as a result of the increase in R&D spending, which in turn led to a decrease in owners' equity.

II. SHAREHOLDER INFORMATION

(i) Total number of ordinary shareholders, number of preferred shareholders with restored voting rights, and shareholding of the top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period		7,618	Total number of preferred shareholders with restored voting rights as at the end of the Reporting Period (if any)		N/A		
Shareholding of the top ten shareholders (excluding shares re-lent)							
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Number of restricted shares including shares re-lent	Shares pledged, marked or frozen	
						Share status	Quantity
HKSCC NOMINEES LIMITED	Unknown	189,566,728	34.83	0	0	Unknown	-
Yantai Rongda Venture Capital Center (Limited Partnership)	Domestic non-state-owned legal person	102,381,891	18.81	102,381,891	102,381,891	Nil	0
FANG JIANMIN	Overseas natural person	26,218,320	4.82	26,218,320	26,218,320	Nil	0

Yantai Rongqian Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	18,507,388	3.40	18,507,388	18,507,388	Nil	0
Yantai Rongyi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	16,630,337	3.06	16,630,337	16,630,337	Nil	0
PAG Growth Prosperity Holding I (HK) Limited	Overseas legal person	14,263,276	2.62	0	0	Nil	0
I-Nova Limited	Overseas legal person	13,600,000	2.50	13,600,000	13,600,000	Nil	0
Yantai Rongshi Enterprise Management Center (Limited Partnership)	Domestic non-state-owned legal person	9,190,203	1.69	9,190,203	9,190,203	Nil	0
Beijing Lapam Healthcare Investment Center (Limited Partnership)	Domestic non-state-owned legal person	7,538,084	1.38	0	0	Nil	0
China Minsheng Banking Corp., Ltd. - BOC Innovative Health Care Balanced Fund	Others	6,190,564	1.14	0	0	Nil	0

Shareholding of the top ten holders of unrestricted shares (excluding shares re-lent)			
Name of shareholder	Number of unrestricted outstanding shares held	Share type and quantity	
		Share type	Quantity
HKSCC NOMINEES LIMITED	189,566,728	Overseas listed foreign shares	189,566,728
PAG Growth Prosperity Holding I (HK) Limited	14,263,276	RMB-denominated ordinary shares	14,263,276
Beijing Lapam Healthcare Investment Center (Limited Partnership)	7,538,084	RMB-denominated ordinary shares	7,538,084
China Minsheng Banking Corp., Ltd. - BOC Innovative Health Care Balanced Fund	6,190,564	RMB-denominated ordinary shares	6,190,564
Agricultural Bank of China Limited - Penghua Medical Tech Equity Securities Investment Fund	4,676,823	RMB-denominated ordinary shares	4,676,823
Luthai Textile Co., Ltd.	3,918,265	RMB-denominated ordinary shares	3,918,265
Bank of China Limited - E Fund Healthcare Sector Hybrid Fund	3,908,065	RMB-denominated ordinary shares	3,908,065

China Merchants Bank Co., Ltd. - Huitianfu Medical Services Flexible Allocation Hybrid Securities Investment Fund	3,179,306	RMB-denominated ordinary shares	3,179,306
YU ZHIHUA	3,122,845	RMB-denominated ordinary shares	3,122,845
Shanghai Liyi Investment Management Partnership (Limited Partnership) - Suzhou Likang Equity Investment Center (Limited Partnership)	3,062,235	RMB-denominated ordinary shares	3,062,235
Description of the connected relationship or concerted actions among the above shareholders	Yantai Rongda Venture Capital Center (Limited Partnership), FANG JIANMIN and I-Nova Limited had a relationship of acting in concert		

Description of participation of top ten shareholders and top ten holders of unrestricted shares in margin trading and re-lending business (if any)	Luthai Textile Co., Ltd. re-lent 1,425,000 shares at the beginning of the Reporting Period, and all the shares were returned at the end of the Reporting Period
--	---

Note 1: As of the end of the Reporting Period, there were a total number of 7,594 Class A ordinary shareholders and 24 Class H ordinary shareholders, totalling 7,618 ordinary shareholders.

Note 2: The shares held by HKSCC NOMINEES LIMITED (香港中央結算(代理人)有限公司) are shares it holds on behalf of several clients, and part of the H shares held by I-Nova Limited are registered under HKSCC Nominees Limited.

Participation of Shareholders with more than 5% shareholding, top ten shareholders and top ten holders of unrestricted outstanding shares in re-lending business

Applicable Not Applicable

Unit: share

Participation of Shareholders with more than 5% shareholding, top ten shareholders and top ten holders of unrestricted outstanding shares in re-lending business								
Name of shareholder (full name)	Shares held in ordinary account and credit account at the beginning of the period		Shares re-lent and not yet returned at the beginning of the period		Shares held in ordinary account and credit account at the end of the period		Shares re-lent and not yet returned at the end of the period	
	Total number	Ratio (%)	Total number	Ratio (%)	Total number	Ratio (%)	Total number	Ratio (%)
Luthai Textile Co., Ltd.	2,493,265	0.46	1,425,000	0.26	3,918,265	0.72	0	0.00

Changes in top ten shareholders and top ten holders of unrestricted outstanding shares from the previous period attributable to re-lending/returning

Applicable Not Applicable

III. OTHER REMINDERS

Other important information about the operation of the Company during the Reporting Period that investors should be reminded of

Applicable Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS**(i) Types of audit opinions**

Applicable Not Applicable

(ii) Financial statements**Consolidated Balance Sheet**

September 30, 2024

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	September 30, 2024	December 31, 2023
Current assets:		
Cash and bank balances	664,964,952.00	743,392,716.82
Held-for-trading financial assets	260,179,555.56	-
Bills receivable	147,677,318.74	78,695,674.95
Accounts receivable	334,428,984.96	297,677,608.93
Receivables financing	51,264,381.26	44,044,931.02
Prepayments	287,105,369.05	270,294,849.12
Other receivables	29,200,438.94	29,011,543.89
Inventories	745,387,541.34	741,559,576.19
Other current assets	3,798,780.51	24,255,054.24
Total current assets	2,524,007,322.36	2,228,931,955.16
Non-current assets:		
Long-term equity investments	8,850,545.83	2,705,448.20
Investments in other equity instruments	53,840,867.96	93,521,672.55
Other non-current financial assets	3,038,731.56	2,000,000.00
Fixed assets	2,412,993,585.31	2,031,305,563.72
Construction in progress	309,112,443.03	795,718,495.54
Right-of-use assets	108,139,896.18	132,248,412.02
Intangible assets	142,680,567.46	143,781,479.65
Long-term deferred expenses	5,493,772.56	6,833,576.52
Other non-current assets	144,555,680.75	91,194,101.23
Total non-current assets	3,188,706,090.64	3,299,308,749.43
Total assets	5,712,713,413.00	5,528,240,704.59
Current liabilities:		

Short-term borrowings	1,026,766,746.38	284,276,638.87
Notes payable	-	13,994,347.44
Accounts payable	184,834,362.99	125,336,595.88
Contract liabilities	3,220,361.43	11,398,410.09
Payroll payable	199,275,853.26	194,940,951.34
Taxes payable	40,837,332.71	34,694,547.74
Other payables	272,540,452.82	391,160,258.67
Non-current liabilities due within one year	118,158,847.27	60,443,433.90
Other current liabilities	15,154,007.15	11,877,366.49
Total current liabilities	1,860,787,964.01	1,128,122,550.42
Non-current liabilities:		
Long-term borrowings	1,341,279,937.63	840,588,019.63
Lease liabilities	46,536,564.21	74,675,060.11
Deferred income	95,428,408.34	46,075,693.04
Deferred tax liabilities	-	1,511,227.50
Total non-current liabilities	1,483,244,910.18	962,850,000.28
Total liabilities	3,344,032,874.19	2,090,972,550.70
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	544,332,083.00	544,263,003.00
Capital reserve	6,287,590,554.06	6,237,868,188.53
Less: Treasury shares	444,896,381.34	440,310,281.32
Other comprehensive income	-93,408,689.99	-51,042,368.30
Retained earnings	-3,924,937,026.92	-2,853,510,388.02
Total equity attributable to owners (or shareholders) of the parent company	2,368,680,538.81	3,437,268,153.89
Total owners' equity (or shareholders' equity)	2,368,680,538.81	3,437,268,153.89
Total liabilities and owners' equity (or shareholders' equity)	5,712,713,413.00	5,528,240,704.59

The Company's legal
representative:
Wang Weidong

Person in charge of
accounting function:
Tong Shaojing

Person in charge of the
accounting department:
Wei Jianliang

Consolidated Statement of Income

January-September 2024

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2024 (January-September)	First three quarters of 2023 (January-September)
------	--	--

I. Total operating revenue	1,208,874,280.23	769,470,314.65
Including: Operating revenue	1,208,874,280.23	769,470,314.65
II. Total operating costs	2,316,244,667.13	1,819,967,398.27
Including: Operating costs	244,744,865.10	177,798,986.36
Taxes and surcharges	11,272,616.41	5,878,516.91
Selling expenses	622,700,750.52	539,790,867.31
Administrative expenses	234,621,471.72	242,865,841.79
R&D expenses	1,153,407,440.34	857,977,852.40
Finance costs	49,497,523.04	-4,344,666.50
Including: Interest expenses	55,598,761.08	13,656,827.51
Interest income	8,544,332.69	19,054,230.73
Add: Other income	65,240,530.15	33,966,289.80
Gain from investment (loss denoted by “-”)	1,241,939.00	1,473,364.03
Including: Gain from investments in associates and joint ventures	-104,902.37	-45,133.39
Gain on derecognition of financial assets measured at amortised cost	1,360,416.66	1,518,497.42
Gain from changes in fair value (loss denoted by “-”)	718,287.12	5,169,310.95
Credit impairment loss (loss denoted by “-”)	-5,774,013.88	-6,247,338.71
Asset impairment loss (loss denoted by “-”)	-10,006,510.93	-8,671,903.11
Gain on disposal of assets (loss denoted by “-”)	88,364.48	-
III. Operating profit (loss denoted by “-”)	-1,055,861,790.96	-1,024,807,360.66
Add: Non-operating income	1,565,965.93	71,134.69
Less: Non-operating expenses	17,130,813.87	5,849,633.63
IV. Total profit (total loss denoted by “-”)	-1,071,426,638.90	-1,030,585,859.60
Less: Income tax expenses	-	-
V. Net profit (net loss denoted by “-”)	-1,071,426,638.90	-1,030,585,859.60
(i) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	-1,071,426,638.90	-1,030,585,859.60
(ii) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	-1,071,426,638.90	-1,030,585,859.60
VI. Other comprehensive income, net of tax	-42,366,321.69	-7,908,770.97

(i) Other comprehensive income attributable to owners of the parent company, net of tax	-42,366,321.69	-7,908,770.97
1. Other comprehensive income not to be reclassified to profit or loss	-38,099,566.59	-8,472,565.88
(1) Changes in fair value of other equity instruments investments	-38,099,566.59	-8,472,565.88
2. Other comprehensive income to be reclassified to profit or loss	-4,266,755.10	563,794.91
(1) Translation differences of the financial statements in foreign currency	-4,266,755.10	563,794.91
VII. Total comprehensive income	-1,113,792,960.59	-1,038,494,630.57
(i) Total comprehensive income attributable to owners of the parent company	-1,113,792,960.59	-1,038,494,630.57
VIII. Earnings per share:		
(i) Basic earnings per share (RMB/share)	-1.99	-1.91
(ii) Diluted earnings per share (RMB/share)	-1.99	-1.91

In case of a business combination under common control during the period, the net profit of the combined party which has been realised prior to the combination was RMB0, and the net profit of the combined party which has been realised in the previous period was RMB0.

The Company's legal representative:
Wang Weidong

Person in charge of accounting function:
Tong Shaojing

Person in charge of the accounting department:
Wei Jianliang

Consolidated Statement of Cash Flows

January-September 2024

Prepared by: RemeGen Co., Ltd.*

Unit: RMB Currency: Renminbi Audit type: Unaudited

Item	First three quarters of 2024 (January-September)	First three quarters of 2023 (January-September)
I. Cash flows from operating activities:		
Cash receipts from sales of goods and provision of services	1,097,729,076.75	591,572,268.92
Tax refund received	14,112,207.51	79,616,190.57

Cash received from other operating activities	110,331,330.11	46,957,338.20
Sub-total of cash inflows from operating activities	1,222,172,614.37	718,145,797.69
Cash paid for goods and services	103,969,884.33	212,674,329.63
Cash paid to and on behalf of employees	837,884,001.41	747,144,842.68
Cash paid for taxes and levies	37,431,526.62	14,431,136.99
Cash paid for other operating activities	1,077,990,268.89	858,657,669.07
Sub-total of cash outflows from operating activities	2,057,275,681.25	1,832,907,978.37
Net cash flows from operating activities	-835,103,066.88	-1,114,762,180.68
II. Cash flows from investment activities:		
Cash received from the disposal of investments	520,078,626.05	788,000,000.00
Cash received from investment income	1,360,416.66	4,809,358.89
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	5,461,797.61	700.00
Cash received from other investment activities	13,994,347.44	54,145,233.66
Sub-total of cash inflows from investment activities	540,895,187.76	846,955,292.55
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	179,951,645.19	712,356,375.91
Cash paid for investments	786,750,000.00	1,039,003,578.83
Cash paid for other investment activities	-	15,964,000.00
Sub-total of cash outflows from investment activities	966,701,645.19	1,767,323,954.74
Net cash flows from investing activities	-425,806,457.43	-920,368,662.19
III. Cash flows from financing activities:		
Cash received from capital contributions	1,032,897.91	31,702,965.39
Cash received from borrowings	1,315,592,447.57	627,581,208.79
Sub-total of cash inflows from financing activities	1,316,625,345.48	659,284,174.18
Cash paid for repayment of debts	1,569,400.00	-
Cash paid for distribution of dividends or profits or settlement of interest	53,218,519.45	11,026,941.56
Cash paid for other financing activities	59,778,979.19	136,628,651.43
Sub-total of cash outflows from financing activities	114,566,898.64	147,655,592.99

Net cash flows from financing activities	1,202,058,446.84	511,628,581.19
IV. Effects of changes in exchange rate on cash and cash equivalents	-5,694,629.93	417,029.52
V. Net increase in cash and cash equivalents	-64,545,707.40	-1,523,085,232.15
Add: Balance of cash and cash equivalents at the beginning of the period	726,551,931.36	2,069,180,189.50
VI. Balance of cash and cash equivalents at the end of the period	662,006,223.96	546,094,957.35

The Company's legal representative:
Wang Weidong

Person in charge of accounting function:
Tong Shaojing

Person in charge of the accounting department:
Wei Jianliang

Adjustment of the financial statements for the beginning of 2024 when the Company implements the new accounting standards or interpretations for the first time

Applicable Not Applicable

This is hereby notified.

Board of directors of RemeGen Co., Ltd.*
October 29, 2024